VoxCell, a Canadian biotechnology company advancing high-resolution, vascularized 3D tissue models, has appointed Graham Craig as Chief Commercial Officer (CCO).

Craig joins VoxCell from clinical-stage biotechnology company, AbCellera, and brings more than 18 years of experience in commercialization and strategic partnerships across the pharmaceutical and biotech sectors. In his new role, his key responsibilities will be to lead VoxCell’s commercial strategy, including global business development, strategic partnerships, and go-to-market execution as the industry accelerates adoption of New Approach Methodologies (NAMs).

“Craig is a commercial leader with deep experience translating complex life-science platforms into customer value and scalable revenue,” said Karolina Valente, Founder, CEO, and CSO of VoxCell. “As regulators move to modernize nonclinical testing expectations and the industry increases investment in NAMs, VoxCell is well-positioned to help drug developers generate more human-relevant data earlier. Craig’s leadership will strengthen our ability to serve pharmaceutical companies, CROs, and research institutions as they adapt to this transition.”

Experience

At AbCellera, Craig was Director of Corporate Development, where he was responsible for the identification, evaluation, and integration of new enabling technologies. Before this, he worked for STEMCELL Technologies Inc, leading several high-profile corporate initiatives, and spent seven years as a commercial strategy consultant for IQVIA Inc., supporting pharmaceutical companies across Europe, Asia, and North America.

“VoxCell is addressing a clear and growing market need for the provision of preclinical translation through models that more closely reflect human biology,” said Craig. “With increasing regulatory and industry alignment on NAMs, our vascularized tissue models offer a compelling path to quickly generate decision-enabling data, helping teams prioritize the right programs earlier and reduce late-stage failure risk.”